BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22851969)

  • 1. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.
    Parenti G; Zampetti B; Rapizzi E; Ercolino T; Giachè V; Mannelli M
    J Oncol; 2012; 2012():872713. PubMed ID: 22851969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic pheochromocytoma and paraganglioma.
    Angelousi A; Kassi E; Zografos G; Kaltsas G
    Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phaeochromocytoma: a catecholamine and oxidative stress disorder.
    Pacak K
    Endocr Regul; 2011 Apr; 45(2):65-90. PubMed ID: 21615192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
    Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
    Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Literature review in the diagnosis and treatment of malignant pheochromocytomas and paragangliomas.].
    Militello C; Jorge C; Pisani J; Cenice F; Chagra C
    Arch Esp Urol; 2020 Sep; 73(7):611-623. PubMed ID: 32886076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.
    Pamporaki C; Berends AMA; Filippatos A; Prodanov T; Meuter L; Prejbisz A; Beuschlein F; Fassnacht M; Timmers HJLM; Nölting S; Abhyankar K; Constantinescu G; Kunath C; de Haas RJ; Wang K; Remde H; Bornstein SR; Januszewicz A; Robledo M; Lenders JWM; Kerstens MN; Pacak K; Eisenhofer G
    Lancet Digit Health; 2023 Sep; 5(9):e551-e559. PubMed ID: 37474439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
    Benn DE; Gimenez-Roqueplo AP; Reilly JR; Bertherat J; Burgess J; Byth K; Croxson M; Dahia PL; Elston M; Gimm O; Henley D; Herman P; Murday V; Niccoli-Sire P; Pasieka JL; Rohmer V; Tucker K; Jeunemaitre X; Marsh DJ; Plouin PF; Robinson BG
    J Clin Endocrinol Metab; 2006 Mar; 91(3):827-36. PubMed ID: 16317055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear medicine therapy of pheochromocytoma and paraganglioma.
    Troncone L; Rufini V
    Q J Nucl Med; 1999 Dec; 43(4):344-55. PubMed ID: 10731785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
    Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.
    Andersen KF; Altaf R; Krarup-Hansen A; Kromann-Andersen B; Horn T; Christensen NJ; Hendel HW
    Cancer Treat Rev; 2011 Apr; 37(2):111-9. PubMed ID: 20675056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
    Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
    Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pediatric pheochromocytoma and paraganglioma: an update].
    Garnier S; Réguerre Y; Orbach D; Brugières L; Kalfa N
    Bull Cancer; 2014 Oct; 101(10):966-75. PubMed ID: 25373696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
    Granberg D; Juhlin CC; Falhammar H
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.
    Dahia PLM; Clifton-Bligh R; Gimenez-Roqueplo AP; Robledo M; Jimenez C
    Endocr Relat Cancer; 2020 Aug; 27(8):T41-T52. PubMed ID: 32069214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas.
    Amar L; Peyrard S; Rossignol P; Zinzindohoue F; Gimenez-Roqueplo AP; Plouin PF
    Ann N Y Acad Sci; 2006 Aug; 1073():383-91. PubMed ID: 17102107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.
    Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.